Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a significant advancement in heart failure therapy, combining an ...

An initiative launched by the American Heart Association in September aims to improve in-hospital patient care for patients with HFpEF and HFmrEF.

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

San Francisco, CA, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Eko, a digital health company applying artificial intelligence (AI) in the fight against heart disease, today announced the U.S. Food and Drug ...

Improvements in optimal medical therapy for patients with heart failure with reduced ejection fraction (HFrEF) have helped reduce the risk of sudden cardiac death (SCD)—in the modern era, though, just ...

PUMPING FOR LIFE: Ejection fraction is a measure of how much blood your heart is pumping. With each heartbeat, the heart contracts and relaxes. As it contracts, the left and right ventricles eject ...

Series A financing will advance the company’s lead candidate for heart failure with reduced ejection fraction (HFrEF) through completion of early clinical development and GMP manufacturing scale-up ...